Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389304 | 0.93 | GPR119 (0.77) | GPR119CYP2C9KCNH2 | |
| SCHEMBL1069622 | 0.93 | GPR119 (0.76) | GPR119CYP2C9KCNH2 | |
| SCHEMBL388794 | 0.92 | GPR119 (0.70) | GPR119CYP2C9KCNH2 | |
| SCHEMBL388795 | 0.89 | GPR119 (0.69) | GPR119CYP2C9KCNH2 | |
| SCHEMBL388998 | 0.85 | GPR119 (1.00) | GPR119CYP2C9KCNH2 | |
| SCHEMBL390939 | 0.84 | GPR119 (0.76) | GPR119CYP2C9KCNH2 | |
| SCHEMBL389551 | 0.84 | GPR119 (0.76) | GPR119CYP2C9KCNH2 | |
| SCHEMBL388545 | 0.84 | GPR119 (0.78) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12241539 | 0.83 | GPR119 (0.85) | GPR119CYP2C9KCNH2 | |
| SCHEMBL388939 | 0.83 | GPR119 (0.73) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, SULT2A1 | GPR119 13/4885CYP2C9 56/4885KCNH2 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.